StockData
Cytokinetics Inc logo

Cytokinetics Inc (CYTK) stock

CYTKNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30
$51.32−0.33 (-0.64%)

Close on Nov 18, 2026Market cap $7.13BP/E –Yield –

Earnings

Cytokinetics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 23, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
$47.60M
+2405.3% on a year earlier
EPS, Q3 FY2026
-$1.37
-$2.55 a year earlier
Latest guidance
Issued
Nov 4, 2026 · 2 items

Quarterly results

Revenue and earnings per share from each of Cytokinetics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Feb 23, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 4, 2026after the close$47.60M+2405.3%-$1.37Release
Q2 FY2026ended Jun 30, 2026Aug 6, 2026after the close$28.60M-57.2%-$1.50Release
Q1 FY2026ended Mar 31, 2026May 5, 2026after the close$19.40M+1112.5%-$1.67Release
Q4 FY2025ended Dec 31, 2025Feb 24, 2026after the close$17.80M+5.3%-$1.50Release
Q3 FY2025ended Sep 30, 2025Nov 5, 2025after the close$1.90M–-$2.55Release
Q2 FY2025ended Jun 30, 2025Aug 7, 2025after the close$66.80M+33300.0%–Release
Q1 FY2025ended Mar 31, 2025May 6, 2025after the close$1.60M+100.0%-$1.36Release
Q4 FY2024ended Dec 31, 2024Feb 27, 2025after the close$16.90M+894.1%–Release
Q2 FY2024ended Jun 30, 2024Aug 8, 2024after the close$200.00K-77.8%-$1.31Release
Q1 FY2024ended Mar 31, 2024May 8, 2024after the close$800.00K-82.6%-$1.33Release
Q4 FY2023ended Dec 31, 2023Feb 27, 2024after the close$1.70M-15.0%-$1.38Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Cytokinetics's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
GAAP combined R&D and SG&A ExpenseGAAPFY2026$860.00M – $890.00M–NewNov 4, 2026
GAAP combined R&D and SG&A ExpenseGAAPFY2026$860.00M – $890.00M$830.00M – $870.00MRaisedAug 6, 2026
Non-cash stock-based compensation expense included in GAAP combined R&D and SG&A ExpenseFY2026$130.00M – $140.00M–NewNov 4, 2026
Non-cash stock-based compensation expense included in GAAP combined R&D and SG&A Expensenon-GAAPFY2026$130.00M – $140.00M–NewAug 6, 2026
Non-cash stock-based compensation expense included in GAAP Combined R&D and SG&A ExpenseFY2026$120.00M – $130.00M$120.00M – $130.00MReaffirmedMay 5, 2026

Guidance history

Every forecast Cytokinetics put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 4, 2026Non-cash stock-based compensation expense included in GAAP combined R&D and SG&A ExpenseFY2026$130.00M – $140.00MNew
Nov 4, 2026GAAP combined R&D and SG&A ExpenseFY2026$860.00M – $890.00MNew
Aug 6, 2026Non-cash stock-based compensation expense included in GAAP combined R&D and SG&A ExpenseFY2026$130.00M – $140.00MNew
Aug 6, 2026GAAP combined R&D and SG&A ExpenseFY2026$860.00M – $890.00MRaised
May 5, 2026GAAP Combined R&D and SG&A ExpenseFY2026$830.00M – $870.00MReaffirmed
May 5, 2026Non-cash stock-based compensation expense included in GAAP Combined R&D and SG&A ExpenseFY2026$120.00M – $130.00MReaffirmed
Feb 24, 2026GAAP Combined R&D and SG&A ExpenseFY2026$830.00M – $870.00MNew
Feb 24, 2026Non-cash stock-based compensation expense included in GAAP Combined R&D and SG&A ExpenseFY2026$120.00M – $130.00MNew
Nov 5, 2025GAAP operating expenseFY2025$680.00M – $700.00MNew
Nov 5, 2025Non-cash stock-based compensation expense included in GAAP operating expenseFY2025$110.00M – $120.00MNew
May 6, 2025Non-cash stock-based compensation expense included in GAAP operating expenseFY2025$110.00M – $120.00MNew
May 6, 2025GAAP operating expenseFY2025$670.00M – $710.00MNew
Aug 8, 2024GAAP Operating ExpenseFY2024$555.00M – $575.00MNew
Aug 8, 2024Non-cash Expense Included in GAAP Operating ExpenseFY2024$105.00M – $110.00MLowered
Aug 8, 2024Net Cash UtilizationFY2024$400.00M – $420.00MLowered
Aug 8, 2024Non-GAAP Operating ExpenseFY2024$445.00M – $470.00MNew
Feb 27, 2024net cash utilizationFY2024$390.00M – $420.00MLowered
Feb 27, 2024operating expensesFY2024$420.00M – $450.00MNew
Feb 27, 2024revenueFY2024$3.00M – $5.00MNew
Aug 3, 2023net cash utilizationFY2023$310.00M – $320.00MLowered

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Cytokinetics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. News
  3. Results
  4. News
  5. Results
  6. Results
  7. Results
  8. News
  9. News
  10. News
  11. News
  12. News
  13. Results
  14. Results
  15. Results

See a number that looks wrong?